NIPPV

Draeger issues recall notification to address potential health risks related to possible separation of breathing hose components in certain breathing circuits

Retrieved on: 
Tuesday, April 18, 2023

For Draeger Neo and Draeger Pediatric disposable breathing systems:

Key Points: 
  • For Draeger Neo and Draeger Pediatric disposable breathing systems:
    A detachment of system components may cause hypoxia due to a loss of airway pressure caused by a leak.
  • Do not depend on any device output (e.g., oxygen desaturation) to make decisions regarding whether to stop using the system.
  • You will also be provided with a Return Material Authorization and pre-paid shipping documents to return the unused product to Draeger.
  • The Draeger Group is currently present in over 190 countries and has more than 16,000 employees worldwide.

Reven Holdings Announces the Publication of a Peer-reviewed Article in the Prestigious Medical Journal Frontiers in Oncology

Retrieved on: 
Friday, November 5, 2021

Reven today announced the publication of a peer-reviewed article in the prestigious medical journal Frontiers in Oncology.

Key Points: 
  • Reven today announced the publication of a peer-reviewed article in the prestigious medical journal Frontiers in Oncology.
  • The article reports a systematic analysis of the antibody responses to COVID-19 vaccination in cancer patients.
  • The article, "Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review," has been published in Frontiers in Oncology, and it is available online.
  • Reven Holdings, Inc., a Delaware corporation, through its Westminster, Colorado based operating company Reven, LLC, is a biopharmaceutical company.

Reven Holdings Announces First Patient Dosed in Double-blind, Randomized, Multi-institutional Phase 2 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Retrieved on: 
Friday, October 22, 2021

Reven had recently announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients.

Key Points: 
  • Reven had recently announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients.
  • Reven today announced that the first patient has been dosed in the randomized, double-blind, placebo-controlled Part 2 portion of the Phase 2 study (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • This FDA-approved controlled clinical trial is aimed at evaluating the efficacy and safety of RJX in side-by-side comparison with a placebo as an adjunct to standard of care in hospitalized COVID-19 patients.
  • Reven Holdings, Inc., a Delaware corporation, through its Westminster, Colorado based operating company Reven, LLC, is a biopharmaceutical company.

Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Retrieved on: 
Friday, September 24, 2021

Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).

Key Points: 
  • Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • We will diligently advance the clinical development of RJX and evaluate its benefit for COVID-19 patients, said Fatih Uckun, MD PhD, the Chief Medical Officer of Reven.
  • It is currently being evaluated as a COVID-19 drug candidate in high risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • Reven Holdings, Inc., a Delaware corporation, through its Westminster, Colorado based operating company Reven, LLC, is a biopharmaceutical company.

Vapotherm to Expand Production Capacity in Advance of Potential Increase in Demand for High-Flow Nasal Cannula Systems for Treating COVID-19 Respiratory Distress

Retrieved on: 
Thursday, June 4, 2020

This expansion is expected to enable the company to increase production of its Precision Flow systems by up to 20X above pre-COVID-19 pandemic levels.

Key Points: 
  • This expansion is expected to enable the company to increase production of its Precision Flow systems by up to 20X above pre-COVID-19 pandemic levels.
  • At maximum capacity, Vapotherms manufacturing increase would create up to an additional 350 manufacturing jobs at its New Hampshire facility.
  • The Precision Flow Hi-VNI system is an advanced high-flow nasal cannula (HFNC) system using high velocity to treat the respiratory distress experienced by COVID-19 patients.
  • Additionally, SCCM further suggests HFNC is preferable to non-invasive positive pressure ventilation (NiPPV) in the management of COVID-19 respiratory distress.

Global Mechanical Ventilators Market Strategy & Insights Report 2019, Featuring Profiles for 60 Players

Retrieved on: 
Friday, June 14, 2019

Non-Invasive Positive Pressure Ventilation (NIPPV) Market: Going Strong

Key Points: 

Non-Invasive Positive Pressure Ventilation (NIPPV) Market: Going Strong
Respiratory Dialysis - An Alternative to Mechanical Ventilation?

U.S. Food and Drug Administration (FDA) Grants Vapotherm Hi-VNI® Technology System a New Product Category

Retrieved on: 
Tuesday, October 9, 2018

EXETER, N.H., Oct.9,2018 /PRNewswire/ --Vapotherm, Inc. (Vapotherm), a leader in advanced respiratory technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Vapotherm's latest version of the Precision Flow product, the Precision Flow Hi-VNI system, a new product category and product code (QAV).

Key Points: 
  • EXETER, N.H., Oct.9,2018 /PRNewswire/ --Vapotherm, Inc. (Vapotherm), a leader in advanced respiratory technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Vapotherm's latest version of the Precision Flow product, the Precision Flow Hi-VNI system, a new product category and product code (QAV).
  • The Vapotherm Precision Flow Hi-VNI system is currently the only product in the QAV category.
  • The historical standard of care for non-invasive management of such patients has been NiPPV, a pressure-based form of non-invasive ventilation.
  • Vapotherm's submission included clinical evidence that Hi-VNI Technology, which is incorporated in all of Vapotherm's Precision Flow products, is non-inferior to NiPPV in preventing mechanical ventilation.

Mechanical Ventilators 2016-2024 - Global Strategic Business Report: NICUs to Provide Lucrative Growth Opportunities

Retrieved on: 
Monday, September 17, 2018

Non-Invasive Positive Pressure Ventilation (NIPPV) Market: Going Strong

Key Points: 

Non-Invasive Positive Pressure Ventilation (NIPPV) Market: Going Strong
Respiratory Dialysis - An Alternative to Mechanical Ventilation?